DURECT Corporation (DRRX)
0.82
-0.01 (-0.61%)
At close: Jan 14, 2025, 3:59 PM
0.85
3.63%
After-hours Jan 14, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 0.6 |
| Market Cap | 25.46M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.64 |
| PE Ratio (ttm) | -1.28 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 0.88 |
| Volume | 169,827 |
| Avg. Volume (20D) | 107,091 |
| Open | 0.82 |
| Previous Close | 0.82 |
| Day's Range | 0.79 - 0.85 |
| 52-Week Range | 0.62 - 1.88 |
| Beta | undefined |
About DRRX
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in...
Sector Healthcare
IPO Date Sep 28, 2000
Employees 48
Stock Exchange NASDAQ
Ticker Symbol DRRX
Website https://www.durect.com
Analyst Forecast
According to 2 analyst ratings, the average rating for DRRX stock is "Hold." The 12-month stock price forecast is $5, which is an increase of 509.61% from the latest price.
Buy 50.00%
Hold 50.00%
Sell 0.00%
Next Earnings Release
DURECT Corporation is scheduled to release its earnings on Mar 26, 2025,
during market hours.
Analysts project revenue of $6.91M, reflecting a 158.90% YoY growth and earnings per share of -0.02, making a -80.00% decrease YoY.
Analysts project revenue of $6.91M, reflecting a 158.90% YoY growth and earnings per share of -0.02, making a -80.00% decrease YoY.
8 months ago ·
Source
-14.02%
DURECT shares are trading lower after the company ...
Unlock content with
Pro Subscription
